|drug2942||SARS-CoV-2 viral composition Wiki||1.00|
|drug3669||Whole Genome Analysis Wiki||1.00|
There is one clinical trial.
In this study (i) the host genome to identify susceptibility regions of infection, inflammation, and host defense, (ii) host response to Severe Acute Respiratory Syndrome-Corona-Virus-2 (SARS-CoV-2) infection, and (iii) viral sequence composition to define viral sequences which may be correlated with disease severity in addition to the metagenome of the throat swab will be analysed .
Description: The change in the genetic makeup of a virus population (measured in numbers) as the viruses mutate and multiply over time at different time pointsMeasure: Viral evolution Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery
Description: CD4+ and CD8+ T cells from blood (per µl) at different time points measuredMeasure: Immune response Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery
Description: Clinical classification according to severity: Light and uncomplicated (mild symptoms) Moderate (mild pneumonia) Severe pneumonia Critical (Acute Respiratory Distress Syndrome (ARDS), sepsis, septic shock) Evaluated at several time pointsMeasure: Disease severity Time: Day 1, Day 3-5, Day 7-9, 48 hours after recovery
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports